AUROPHARMA / NSE / Major Drugs
Aurobindo Pharma
1Y Price Trend
Key Information
Recommendations
RatingBuy
Target High1,550
Target Low1,017
Target Mean2.22
Target Median52.78
Risk Metrics
Overall RiskBalanced risk
Board Risk27.98
Key Analysis
Overall score, performance score, return rating, defensive, aggressive, and balanced views.
Download appProjection Analytics
Best-case, base-case, worst-case, and dynamic AI projection views.
Download appLatest stock news
Voltas, Auro Pharma, Federal Bank: Stocks to trade—check price targets, stop loss & more MSN
Aurobindo Pharma launches TheraNym, India’s largest biologics CMO Indian Pharma Post
USFDA Clears Aurobindo Pharma's Generic Xeljanz Tablets for Arthritis, Ulcerative Colitis Medical Dialogues
Aurobindo Pharma - Retail investors' picks: 11 high-margin stocks surge up to 40% in CY26 The Economic Times
Aurobindo Pharma officials to attend UBS virtual investor meet scanx.trade
Aurobindo Pharma gains on getting USFDA`s final nod for Tofacitinib Tablets Investment Guru India
Aurobindo Pharma Launches TheraNym, Large-Scale Biologics Contract Manufacturing Facility in Telangana Machine Maker
Aurobindo Pharma gains after receiving USFDA approval for Tofacitinib tablets Business Standard
© SharekeyX | Rusaka Technologies 2024-2026

